drugset
Drugs / Hyperimmune globulin
last change Dec 2025 re-read 2 minutes ago

Hyperimmune globulin

also known as COVID-19 Hyper-Immunoglobulin (Human)

Protein / enzyme biologic

Developed for
COVID-19
Investigated by
Aotearoa Clinical Trials · Australasian Society for Infectious Diseases · Australian and New Zealand Intensive Care Research Centre · Hunter Medical Research Institute · The Peter Doherty Institute for Infection and Immunity · University of Melbourne

Trials 1 · a red edge is where a trial was stopped

today NCT04483960 · Ph 3
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04483960 Jul 2020 → Jul 2025 COVID-19 University of Melbourne Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Hyperimmune globulin ClinicalTrials.gov intervention name — accepted as the source's own label NCT04483960 ↗
Known as COVID-19 Hyper-Immunoglobulin (Human) “2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation” NCT04483960 ↗
Modality Protein / enzyme biologic “Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma” NCT04483960 ↗